A number of filgrastim and epoetin alfa biosimilars are available to European oncologists, and since 2015, U.S. oncologists have had access to Zarxio—the first biosimilar launched in the United…
Immune checkpoint inhibitors have entered multiple oncology indications but the high costs associated with these agents present significant challenges for payers. The potential for label expansions…
The large therapeutic market for chronic obstructive pulmonary disease (COPD), a disease that is closely associated with smoking, continues to expand and is expected to grow from approximately $15…
Tens of thousands of Brazilian and Mexican men are diagnosed with prostate cancer every year. In recent years, there have been multiple clinical advances in the field, with new therapies offering…
The rising prevalence in EU5 markets of neuropathic pain associated with multiple conditions represents commercial opportunities for drug manufacturers. However, a growing generic presence among…
Consolidation within the oncology provider community, including hospital acquisitions of oncology practices and oncology practices joining together, is changing the dynamics in the relationship…
Colorectal cancer (CRC) affects several thousands of people in Brazil and Mexico. Once it metastasizes, the only available therapeutic options are premium-priced targeted agents and chemotherapy…
Schizophrenia and major depressive disorder (MDD) are disabling psychiatric conditions that are linked to a heavy economic and disease burden on society and patients as well as their caregivers…
Gram-Negative Infections | Access & Reimbursement | US examines the market access factors that influence commercial success of therapies for the treatment of gram-negative infections. The analysis…
Biomarker-driven prescribing in oncology is playing an increasingly important role in various diseases, from indications in which its use is well entranced such as non-small-cell lung cancer (NSCLC…
The success of an anticancer therapy is not only dependent on the outcome of its pivotal trial, but also on that trial’s design, which is examined by the regulatory bodies, payers, and…
From disease basics to insightful analysis of market dynamics, Glioma | Disease Landscape & Forecast | United States, EU5 provides comprehensive disease coverage addressing critical aspects of the…
The systemic lupus erythematosus (SLE) market in the United States is largely genericized and off-label. With the exception of Benlysta (IV)—which launched in 2011—no new drug has been approved…
This detailed, expanded analysis explores key access and reimbursement topics in the rare disease space in the United States, such as the approaches managed care organizations take to control both…
The prevalence of chronic pain associated with numerous indications (e.g., osteoarthritis, cancer) and of idiopathic origin (e.g., chronic back pain) continues to increase throughout the EU5. The…